comparison of the effectiveness of drug treatment and lifestyle change based on a meta-theoretical model in three indicators of patients with metabolic syndrome in Tehran in 1396

Document Type : Research Paper


1 PHD student in Health Psychology Tehran university of justice

2 Professor and holder of PhD Degree in the field of Psychology, Assistant Professor at Islamic Azad University, Tehran

3 holder of PhD Degree in the field of Psychology, Associate Professor at University of Imam Hossein, Tehran

4 holder of PhD Degree in the field of Psychology, Assistant Professor at University of Kharazmi, Tehran


Introduction:Metabolic syndrome is a collection of the risk factors relevant to the cardiovascular diseases & diabetes and the number of patients who suffer the said syndrome increases every day. This study was performed with the aim of determining the effect of one educational plan based on the model-trans-theory(TTM) and in order to control the risk factors (Especially the Nutrition).
Materials and Methods: This study applies the quasi-experimental research method and with the pre-exam & post-exam plan in the medicine control group and testifier so that a number of 75 individuals who were ill with the metabolic syndrome were included in a simple accidental form and in three groups of 25 individuals. The measuring tool applicable for a 24 hours questionnaire with the food mode and the meta-theory questionnaire of Marcus by which the behavior change stages and behavior process (Self-Efficiency & Decision Making Balance) were first assessed and then taught. Also the data registration sheet was used for gathering the data relevant to the waist size and circumference, systolic and diastolic blood pressure (Hypertension), TG, HDL and FBS and the existence of at least three indexes was taken into consideration as a criterion for determining the metabolic syndrome. Educational intervention was performed in four sessions and for the test group and some required medicines were applied for the medical & testifier groups but without the educational intervention and after collecting the data and the results were obtained after 4 months of educational intervention. Ultimately the said data were analyzed by the independent, dependent T tests, co-variance and SPSS software.
Results: Measuring the change stages structure and prior to the intervention showed that a high percentage of patients were in the preliminary stage (Pre-Contemplation, Contemplation and Readiness) that more than %76/4 of test group individuals remained in the act and retention after the intervention stage.
Conclusion:Metabolic syndrome is one global crisis which threatens the health and economy of the most nations. Scientific evidence shows that a major part of the metabolic syndrome can be preventable and even curable (Treatable) through a change in mediating behaviors especially modifying diet and lifestyle.


2- GM. Role of insulin resistance in human disease. Banding Lecture. Diabetes 1988; 37: 12, 1595-1607.
Alexander CM, Landsman PB, Teutsch SM, etal NCEP defined metabolic syndrome, diabetes and prevalence of
coronary heart disease among NHANES+++ participants age 50 years and older. Diabetes 2003; 52: 1210- 1214.
Alberti G. Introduction to the metabolic syndrome. Eur Heart J2005; 7: D3- D5.
3 Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome.Nature 2006;444:881–887.
4-Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic
syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006; 49:41.
5. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular
disease in people with metabolic syndrome. Diabetes Care 2007; 30:1219.
6. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel
III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as
predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8.
7-Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM,Heine RJ. Metabolic syndrome and 10-year
cardiovascular disease risk inthe Hoorn Study. Circulation 2005; 112:666–673.
8. Bo S, Gentile L, Ciccone G, Baldi C, Benini L, Dusio F, Lucia C,Forastiere G, Nuti C, Cassader M, Franco Pagano
G. The metabolicsyndrome and high C-reactive protein: prevalence and differences by sexin a southern-European
population-based cohort. Diabetes Metab ResRev. 2005; 21:515–524.
9-Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC,Muggeo M. Bruneck Study. Metabolic
syndrome: epidemiology andmore extensive phenotypic description. Cross-sectional data from theBruneck Study. Int J
ObesRelatMetabDisord. 2003; 27:1283–1289.
10-Miccoli R, Bianchi C, Odoguardi L, Penno G, Caricato F, GiovannittiMG, Pucci L, Del Prato S. Prevalence of the
metabolic syndrome amongItalian adults according to ATP III definition. Nutr Metab Cardiovasc Dis. 2005; 15:250 –
11-Maggi S, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F, CrepaldiG; ILSA Working Group. Metabolic
syndrome, diabetes, and cardiovasculardisease in an elderly Caucasian cohort: the Italian LongitudinalStudy on Aging.
J Gerontol A BiolSci Med Sci. 2006; 61:505–510.
12-Lorenzo C, Serrano-Rios M, Martinez- Larrad MT, Gonzalez-Sanchez JL,Seclen S, Villena A, GonzalezVillalpando C, Williams K, HaffnerSM.Geographic variations of the International Diabetes Federation and theNational
Cholesterol Education Program- Adult Treatment Panel III definitionsof the metabolic syndrome in nondiabetic
subjects. DiabetesCare 2006; 29:685– 691
13-Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive
patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac
Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentrerandomised controlled trial. Lancet 2003; 361:
14-NCEP Expert Panel on the Detection and Treatment of High Blood Cholesterol in Adults (ATP III). Third Report of
the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143- 421.
15-Grundy SM, Cleeman JI, Merz CN, et al.Implications of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III guidelines.
16-Elissa Lane Miller, CNM, PhD, Angela Mitchell, FNP, ND. Metabolic Syndrome: Screening, Diagnosis, and
Management. J. Midwif& Women’s Health2006; 51(3) 141- 151.
16-Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated
triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046.
139. Pyörälä K, Ballantyne CM, Gumbiner B, et
17-Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol
Nutr Metab 2007; 32: 76- 88. 9. Bate KL, Jerums G. Preventing complications of diabetes. Med J Aust. 2003; 179(9):
498-503. 10.
18-Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and
financial barriers in a managed care population with diabetes. Diabetes Care 2000; 23(4): 477-83. 11.
19-Siminerio LM, Piatt GA, Emerson S, Ruppert K, Saul M, Solano F, et al. Deploying the chronic care model to
implement and sustain diabetes self- management training programs. Diabetes Educ 2006; 32(2): 253-60.